Symmetrical drug-related intertriginous and flexural exanthema (Baboon syndrome) associated with infliximab

Journal of Dermatological Case Reports

Volumn 9, Issue 1, 2015, Pages 12-14

  Bulur, Isil ^a   Keseroglu, Havva Ozge ^b   Saracoglu, Zeynep Nurhan ^a   Gönül, Müzeyyen ^b  

^a ESKISEHIR OSMANGAZI UNIVERSITY   (Turkey)

^b DISKAPI YILDIRIM BEYAZIT TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Adalimumab; Adverse event; Allergy; Erythema; Methotrexate; Psoriasis; Tumor necrosis factor alpha

Indexed keywords

ADALIMUMAB; ALANINE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; INFLIXIMAB; STEROID;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DRUG ERUPTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PSORIASIS; SKIN BIOPSY; SYMMETRICAL DRUG RELATED INTERTRIGINOUS AND FLEXURAL EXANTHEMA;

EID: 84981731638     PISSN: None     EISSN: 18987249     Source Type: Journal    
DOI: 10.3315/jdcr.2015.1190     Document Type: Article

References (11)

1. Mocci G, Marzo M, Papa A, Armuzzi A, Guidi L. Dermatological adverse reactions during anti-TNF treatments: focus on inflammatory bowel disease. J Crohns Colitis. 2013; 7: 769-779. PMID: 23453887.
2. Hausermann P, Harr T, Birchner AJ. Baboon syndrome resulting from systemic drugs: is there strife between SDRIFE and allergic contact dermatitis syndrome? Contact Derm. 2004; 51: 297-310. PMID: 15606657.
3. Tan SC, Tan JW. Symmetrical drug-related intertriginous and flexural exanthema. Curr Opin Allergy Clin Immunol. 2011; 11: 313-318. PMID: 21659857.
4. Nuno-Gonzalez A, Dehesa L, Ricotti C, Kerdel F. Flexural or inverse psoriasis in a patient with hidradenitis suppurativa receiving treatment with infliximab. Actas Dermosifiliogr. 2012; 103: 936-937. PMID: 23149048.
5. Nguyen K, Vleugels RA, Velez NF, Merola JF, Qureshi AA. Psoriasiform reactions to anti-tumor necrosis factor α therapy. J Clin Rheumatol. 2013; 19: 377-381. PMID: 24048106.
6. Cheifetz A, Mayer L. Monoclonal antibodies, immunogenicity, and associated infusion reactions. Mt Sinai J Med. 2005; 72: 250-256. PMID: 16021319.
7. Kleyn CE, Griffiths CE. Infliximab for the treatment of psoriasis. Expert Opin Biol Ther. 2006; 6: 797-805. PMID: 16856801.
8. Steenholdt C, Svenson M, Bendtzen K, Thomsen OO, Brynskov J, Ainsworth MA. Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2011; 34: 51-58. PMID: 21535447.
9. Miehsler W, Novacek G, Wenzl H, Vogelsang H, Knoflach P, Kaser A, Dejaco C, Petritsch W, Kapitan M, Maier H, Graninger W, Tilg H, Reinisch W; Austrian Society of Gastroenterology and Hepatology. A decade of infliximab: the Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease. J Crohns Colitis. 2010; 4: 221-256. PMID: 21122513.
10. Lecluse LL, Piskin G, Mekkes JR, Bos JD, de Rie MA. Review and expert opinion on prevention and treatment of infliximabrelated infusion reactions. Br J Dermatol. 2008; 159: 527-536. PMID: 18627374.
11. Kavala M, Zindancı I, Turkoglu Z, Can B, Kocaturk E, Senol S, Topaloglu F. Acute generalized exanthematous pustulosis induced by etanercept: another dermatologic adverse effect. Case Rep Dermatol Med. 2013; 2013: 601412. PMID: 23573431.